These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Stimulation of ANP secretion by 2-Cl-IB-MECA through A(3) receptor and CaMKII. Yuan K; Bai GY; Park WH; Kim SZ; Kim SH Peptides; 2008 Dec; 29(12):2216-24. PubMed ID: 18838091 [TBL] [Abstract][Full Text] [Related]
5. Selective A3 adenosine receptor agonist protects against doxorubicin-induced cardiotoxicity. Galal A; El-Bakly WM; Al Haleem EN; El-Demerdash E Cancer Chemother Pharmacol; 2016 Feb; 77(2):309-22. PubMed ID: 26676227 [TBL] [Abstract][Full Text] [Related]
10. Exercise preconditioning protects against doxorubicin-induced cardiac dysfunction. Hydock DS; Lien CY; Schneider CM; Hayward R Med Sci Sports Exerc; 2008 May; 40(5):808-17. PubMed ID: 18408619 [TBL] [Abstract][Full Text] [Related]
11. Activation of adenosine A3 receptors reduces ischemic brain injury in rodents. Chen GJ; Harvey BK; Shen H; Chou J; Victor A; Wang Y J Neurosci Res; 2006 Dec; 84(8):1848-55. PubMed ID: 17016854 [TBL] [Abstract][Full Text] [Related]
12. Acute exercise protects against doxorubicin cardiotoxicity. Wonders KY; Hydock DS; Schneider CM; Hayward R Integr Cancer Ther; 2008 Sep; 7(3):147-54. PubMed ID: 18815146 [TBL] [Abstract][Full Text] [Related]
13. Impairment of the actin-myosin interaction in permeabilized cardiac trabeculae after chronic doxorubicin treatment. Bottone AE; Voest EE; de Beer EL Clin Cancer Res; 1998 Apr; 4(4):1031-7. PubMed ID: 9563899 [TBL] [Abstract][Full Text] [Related]
14. Ferritin heavy chain as main mediator of preventive effect of metformin against mitochondrial damage induced by doxorubicin in cardiomyocytes. Asensio-Lopez MC; Sanchez-Mas J; Pascual-Figal DA; de Torre C; Valdes M; Lax A Free Radic Biol Med; 2014 Feb; 67():19-29. PubMed ID: 24231192 [TBL] [Abstract][Full Text] [Related]
15. Adenosine A(3)-receptor stimulation attenuates postischemic dysfunction through K(ATP) channels. Thourani VH; Nakamura M; Ronson RS; Jordan JE; Zhao ZQ; Levy JH; Szlam F; Guyton RA; Vinten-Johansen J Am J Physiol; 1999 Jul; 277(1):H228-35. PubMed ID: 10409201 [TBL] [Abstract][Full Text] [Related]
16. The A3 adenosine receptor as a new target for cancer therapy and chemoprotection. Fishman P; Bar-Yehuda S; Barer F; Madi L; Multani AS; Pathak S Exp Cell Res; 2001 Oct; 269(2):230-6. PubMed ID: 11570815 [TBL] [Abstract][Full Text] [Related]
17. The influence of the time interval between monoHER and doxorubicin administration on the protection against doxorubicin-induced cardiotoxicity in mice. Bruynzeel AM; Mul PP; Berkhof J; Bast A; Niessen HW; van der Vijgh WJ Cancer Chemother Pharmacol; 2006 Nov; 58(5):699-702. PubMed ID: 16565833 [TBL] [Abstract][Full Text] [Related]
20. Inhibition of cell proliferation through cell cycle arrest and apoptosis by thio-Cl-IB-MECA, a novel A3 adenosine receptor agonist, in human lung cancer cells. Kim SJ; Min HY; Chung HJ; Park EJ; Hong JY; Kang YJ; Shin DH; Jeong LS; Lee SK Cancer Lett; 2008 Jun; 264(2):309-15. PubMed ID: 18321638 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]